EP3411121B1 - Glucose conjugates of triptolide, analogs and uses thereof - Google Patents

Glucose conjugates of triptolide, analogs and uses thereof Download PDF

Info

Publication number
EP3411121B1
EP3411121B1 EP17748283.3A EP17748283A EP3411121B1 EP 3411121 B1 EP3411121 B1 EP 3411121B1 EP 17748283 A EP17748283 A EP 17748283A EP 3411121 B1 EP3411121 B1 EP 3411121B1
Authority
EP
European Patent Office
Prior art keywords
cancer
substituted
unsubstituted
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17748283.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3411121A1 (en
EP3411121A4 (en
Inventor
Jun Liu
Qingli HE
Martin G. Pomper
Ii MINN
Biao Yu
Qiaoling WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP3411121A1 publication Critical patent/EP3411121A1/en
Publication of EP3411121A4 publication Critical patent/EP3411121A4/en
Application granted granted Critical
Publication of EP3411121B1 publication Critical patent/EP3411121B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates generally to anti-cancer compounds and more specifically to glucose conjugates of triptolide and analogs thereof, and methods of treating cancer using such compounds.
  • Triptolide is an active component from the traditional Chinese medicinal plant Thunder God Vine. It has been shown to possess anti-inflammatory, immunosuppressive and anticancer activities, among others. Its molecular target has been identified as the XPB (ERCC3) subunit of the general transcription factor TFIIH. It works by blocking RNAPII transcription initiation and nucleoside excision repair. Triptolide and analogs have been developed as new anticancer and immunosuppressive drugs. Unfortunately, dose-limiting toxicity and insolubility have been major hurdles for its development as a new drug.
  • the present invention is based on the seminal discovery that conjugation of triptolide with glucose to form glucose-triptolide conjugates provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
  • the invention provides an anti-proliferative effective amount of a glucose-triptolide conjugate compound for use in the treatment of cancer.
  • glucose-triptolide conjugate compounds have the structure of Formula I: T&A-L 1 -Sugar (I)
  • the cancer may be one of the following, but not limited to bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, and gastric cancer, cervical cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, leukemia, non-hodgkin's lymphoma, prostate cancer, rectal cancer, malignant melanomas, alimentary/gastrointestinal tract cancer, liver cancer, skin cancer, lymphoma, kidney cancer, muscle cancer, bone cancer, brain cancer, eye or ocular cancer, rectal cancer, colon cancer, cervical cancer, bladder cancer, oral cancer, benign and malignant tumors, stomach cancer, corpus uteri, testicular cancer, renal cancer, throat cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma,
  • the cancer is prostate cancer.
  • the cancer is metastatic cancer.
  • T&A moiety is compound 1 and the sugar is compound 19 , 20 , 37 or 38 .
  • L 1 is a direct bond, -COCH 2 CH 2 CO-, or -CH 2 -.
  • T&A moiety is compound 1 and the sugar is compound 19 .
  • glucose triptolide conjugate compound has a Formula G1-9.
  • the compound is Formula G4.
  • Formula G1-9 are illustrated in the structures provided herein.
  • the invention also provides a pharmaceutical composition comprising the compounds listed above.
  • the method of treatment includes administration intravenously, such as at a dosage of about 0.1 mg/kg to 2 mg/kg per dosage.
  • the compound is administered once daily for up to about 4 weeks.
  • the method may further include administering a chemotherapeutic compound, for example, prior to, simultaneously with, or following administration of a compound of the invention.
  • the method of synthesizing a glucose-triptolide conjugate compound includes synthetic scheme II or III. These schemes are provided herein.
  • an anti-proliferative effective amount of a glucose-triptolide conjugate compound is administered to a subject in a method to treat possible organ rejection in subjects that have undergone an organ transplant.
  • an anti-proliferative effective amount of a glucose-triptolide conjugate compound is administered to a subject in a method to treat autoimmune diseases.
  • immune related diseases include but are not limited to: Acute disseminated encephalomyelitis (ADEM), Addison's disease, Ankylosing spondylitis, Antiphospholipid antibody syndrome, Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune Lymphoproliferative Syndrome (ALPS), Autoimmune polyendocrine/polyglandular syndrome, Autoimmune thrombocytoipenia purpura, Balo disease, Behcet disease, Bullous pemphigoid, Cardiomyopathy, Celiac sprue-dermatitis herpetiformis, Chronic fatigue immune dysfunction syndrome (CFIDS), Chronic inflammatory demyelinating neuropathy, Cicatrical pemphigoid, Coeliac disease, Cold agglutinin disease, CREST syndrome, Crohn's disease, Cystic fibrosis, Degos disease, Dermatomyositis, Diabetes (Type I or Ju
  • a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating cancer.
  • a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating possible organ rejection.
  • a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating autoimmune disease.
  • the present invention is based on trying to solve the issues of solubility and toxicity associated with triptolide. It was hypothesized that if triptolide could be conjugated to glucose, the two aforementioned problems associated with triptolide could be addressed.
  • the glucose-triptolide conjugates would be preferentially taken up by cancer cells and they should also exhibit much higher water solubility due to the water solubility of glucose moiety.
  • cancer or "cancerous growth” means the uncontrolled, abnormal growth of cells and includes within its scope all the well-known diseases that are caused by the uncontrolled and abnormal growth of cells.
  • Non-limiting examples of common cancers include bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, and gastric cancer, cervical cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, leukemia (e.g. myeloid, lymphocytic, myelocytic and lymphoblastic leukemias), non-hodgkin's lymphoma, prostate cancer, rectal cancer, and malignant melanomas.
  • leukemia e.g. myeloid, lymphocytic, myelocytic and lymphoblastic leukemias
  • non-hodgkin's lymphoma prostate cancer, rectal cancer, and malignant melanomas.
  • chemotherapeutic agents can be used prior to, simultaneously with or following treatment with invention compounds.
  • Illustrative agents include but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
  • Therapeutic antibodies or other proteins are also envisioned in combination therapies of the invention.
  • This example illustrates the synthesis of glucose-conjugated triptolide compounds.
  • Five glucose conjugates with different types of linkers connecting glucose to triptolide were synthesized, designated G1--G5 (schemes I-III).
  • the Octanol-water partition coefficient, LogP were significantly improved over triptolide itself ( Fig. 1 ).
  • the activity of the different glucose-triptolide conjugates was assessed in vitro ( Fig. 2 ). It was found that they differ in their anti-proliferative activity as measured by tritiated thymidine incorporation with G4 and G3 showing moderate activity, while G1, G2 and G5 exhibiting significantly reduced activity. The ability of the glucose conjugates to inhibit the ATPase activity of XPB in the TFIIH complex was also addressed. Interestingly, none of the five glucose conjugates showed appreciable inhibitory activity, suggesting that the cellular activity was a result of breakdown of the conjugates either in cell culture or upon entry into cells.
  • the in vivo antitumor activity of the glucose-triptolide conjugate G4 was determined using an established metastatic prostate cancer model (Reference 1).
  • the luciferase---expressing prostate cancer line PC3/ML was injected into NOD/SCID/IL2r ⁇ null (NSG) mice through the tail vein.
  • NSG NOD/SCID/IL2r ⁇ null mice
  • the metastasis of the injected prostate cancer cells into liver, kidney, lung and bone can be monitored in live animals by bioluminescent imaging (BLI). It was shown that this is a reliable model with reproducible liver metastasis and all animals succumb by Week 7 after injection of cells (or Week 4 after initiation of treatments).
  • mice treated with 11 had lower tumor burden during Weeks 1 and 2 compared with those treated with triptolide.
  • both treatment groups showed undetectable tumor cells while all animals in the untreated groups died.
  • tumors immediately returned in animals treated with triptolide. But no tumor cells were detectable in those treated with G4 till the end of the experiment, revealing sustained anticancer activity of G4 in vivo.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
EP17748283.3A 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof Active EP3411121B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291416P 2016-02-04 2016-02-04
PCT/US2017/016527 WO2017136739A1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Publications (3)

Publication Number Publication Date
EP3411121A1 EP3411121A1 (en) 2018-12-12
EP3411121A4 EP3411121A4 (en) 2019-12-18
EP3411121B1 true EP3411121B1 (en) 2024-09-11

Family

ID=59500284

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17748283.3A Active EP3411121B1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Country Status (8)

Country Link
US (2) US10695319B2 (enExample)
EP (1) EP3411121B1 (enExample)
JP (1) JP7042744B2 (enExample)
CN (1) CN108601952B (enExample)
AU (1) AU2017214572A1 (enExample)
CA (1) CA3013619A1 (enExample)
MX (1) MX2018009406A (enExample)
WO (1) WO2017136739A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN109897053B (zh) * 2019-03-28 2020-05-29 中国医学科学院医药生物技术研究所 雷斯吲哚甲及其制备方法和抗丙型肝炎病毒用途
CN111040018A (zh) * 2019-12-30 2020-04-21 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 丙烯酸雷公藤甲素酯、其制备方法及其应用
EP4086271B1 (en) 2019-12-30 2023-12-13 Guangdong Provincial Hospital of TCM Triptolide acrylate, preparation method therefor and use thereof
EP4114468A4 (en) * 2020-03-02 2025-04-09 The Johns Hopkins University GLUCOSETRIPTOLIDE CONJUGATES AND USES THEREOF
JP2023538424A (ja) * 2020-08-21 2023-09-07 ルヤン コーポレイション トリプトリドコンジュゲートおよびその使用
CN115286684A (zh) * 2022-05-20 2022-11-04 福建医科大学 一种糖与雷公藤内酯醇或其衍生物的缀合物及其制备方法与应用
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218367B1 (en) * 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
US6620843B2 (en) 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
CA2448795A1 (en) 2001-03-15 2002-09-26 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent
US9150600B2 (en) * 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2013, HAMADA HIROKI ET AL: "Chemo-enzymatic Synthesis of Propionyl-ester-linked Taxol-monosaccharide Conjugate and its Drug Delivery System Using Hybrid-Bio-nanocapsules Targeting Brain Glioma Cells.", Database accession no. NLM24665217 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 25 March 2013 (2013-03-25), LIU PENGXING ET AL: "Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties.", Database accession no. NLM23420130 *
HAMADA HIROKI ET AL: "Chemo-enzymatic Synthesis of Propionyl-ester-linked Taxol-monosaccharide Conjugate and its Drug Delivery System Using Hybrid-Bio-nanocapsules Targeting Brain Glioma Cells.", CLINICAL MEDICINE INSIGHTS. WOMEN'S HEALTH 2013, vol. 6, 2013, pages 71 - 75, XP002793229, ISSN: 1179-562X, DOI: 10.4137/CMWH.S8213 *
LIU PENGXING ET AL: "Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties.", CHEMICAL COMMUNICATIONS (CAMBRIDGE, ENGLAND) 25 MAR 2013, vol. 49, no. 24, 25 March 2013 (2013-03-25), pages 2421 - 2423, XP002793228, ISSN: 1364-548X, DOI: 10.1039/c3cc38589b *

Also Published As

Publication number Publication date
JP2019509986A (ja) 2019-04-11
US20200297693A1 (en) 2020-09-24
EP3411121A1 (en) 2018-12-12
CA3013619A1 (en) 2017-08-10
MX2018009406A (es) 2018-11-09
CN108601952A (zh) 2018-09-28
CN108601952B (zh) 2022-03-04
EP3411121A4 (en) 2019-12-18
US10695319B2 (en) 2020-06-30
AU2017214572A1 (en) 2018-08-16
JP7042744B2 (ja) 2022-03-28
WO2017136739A1 (en) 2017-08-10
US20190038596A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
EP3411121B1 (en) Glucose conjugates of triptolide, analogs and uses thereof
Nakada et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
JP2019504100A5 (enExample)
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
JP2019529444A5 (enExample)
CN111836814A (zh) 稠环化合物、其制备方法及用途
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
JP2019509986A5 (enExample)
JP2019524713A5 (enExample)
WO2016024595A1 (ja) エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物
TWI615145B (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
WO2007023778A1 (ja) 新規抗癌併用薬
CN108498518B (zh) 七元环小檗碱类似物及其药物组合物在制备治疗多发性骨髓瘤的药物中的应用
ES2910659T3 (es) Nuevo derivado de PEG
JP6488280B2 (ja) タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
CN111773388A (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
CN117138054A (zh) 雷公藤甲素的多肽缀合物及其用途
JPWO2020011724A5 (enExample)
BR112023022531B1 (pt) CONJUGADO DE FÁRMACO E ANTICORPO ANTI-c-Met, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS E SEU USO NO TRATAMENTO DE CÂNCER PULMONAR DE CÉLULAS NÃO PEQUENAS
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
HK1240958A1 (en) Peg derivative
CN102370986A (zh) 含羟甲基酞胺哌啶酮衍生物的药物组合物及其制备和应用
MY144013A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
TW201336493A (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎小兒藥用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180815

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: POMPER, MARTIN, G.

Inventor name: HE, QINGLI

Inventor name: LIU, JUN

Inventor name: YU, BIAO

Inventor name: MINN, II

Inventor name: WANG, QIAOLING

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101AFI20190808BHEP

Ipc: A61K 31/365 20060101ALI20190808BHEP

Ipc: A61P 37/06 20060101ALI20190808BHEP

Ipc: C07D 493/22 20060101ALI20190808BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259645

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20191120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101AFI20191114BHEP

Ipc: A61P 37/06 20060101ALI20191114BHEP

Ipc: A61K 31/365 20060101ALI20191114BHEP

Ipc: C07D 493/22 20060101ALI20191114BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HE, QINGLI

Inventor name: LIU, JUN

Inventor name: YU, BIAO

Inventor name: MINN, II

Inventor name: POMPER, MARTIN, G.

Inventor name: WANG, QIAOLING

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201112

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ipc: A61K0031365000

Ref document number: 602017084794

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61P0035000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 493/22 20060101ALI20231109BHEP

Ipc: A61P 37/06 20060101ALI20231109BHEP

Ipc: A61P 35/00 20060101ALI20231109BHEP

Ipc: A61K 31/365 20060101AFI20231109BHEP

INTG Intention to grant announced

Effective date: 20231121

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240429

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017084794

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241211

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241212

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241211

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241211

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241212

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1722086

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250111

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250227

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017084794

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20250612

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1259645

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602017084794

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240911

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250228